Production (Stage)
Compass Therapeutics, Inc.
CMPX
$2.41
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | 850.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | 850.00K | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | -- | 850.00K | -- |
| SG&A Expenses | 4.91M | 3.54M | 3.63M | 4.72M | 3.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.97M | 16.57M | 12.24M | 15.90M | 12.77M |
| Operating Income | -17.97M | -16.57M | -12.24M | -15.05M | -12.77M |
| Income Before Tax | -16.63M | -15.03M | -10.48M | -13.08M | -10.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.63M | -15.03M | -10.48M | -13.08M | -10.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.63M | -15.03M | -10.48M | -13.08M | -10.79M |
| EBIT | -17.97M | -16.57M | -12.24M | -15.05M | -12.77M |
| EBITDA | -17.83M | -16.43M | -12.10M | -14.89M | -12.62M |
| EPS Basic | -0.12 | -0.11 | -0.08 | -0.10 | -0.08 |
| Normalized Basic EPS | -0.08 | -0.07 | -0.05 | -0.06 | -0.05 |
| EPS Diluted | -0.12 | -0.11 | -0.08 | -0.10 | -0.08 |
| Normalized Diluted EPS | -0.08 | -0.07 | -0.05 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 138.24M | 136.63M | 137.59M | 137.59M | 136.61M |
| Average Diluted Shares Outstanding | 138.24M | 136.63M | 137.59M | 137.59M | 136.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |